Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 8,258,257 | 09/04/2012 | 2008-495 |
Vaccines have a total market size of around $32 billion (2016). This market is estimated to reach the level of nearly $48 billion by 2021, resulting in a compound annual growth rate (CAGR) of 8.3%.
Prof. David Lo and his colleagues at the University of Riverside have developed a novel peptide, CPE, that targets M cells. This novel peptide was conjugated to a recombinant influenza hemagglutinin and delivered with a cholera toxin intranasally to a mouse model. The subject mouse exhibited a strong IgA and IgG1 isotype response indicating that a strong Th2 response was elicited. As shown in the bar graphs below, after an initial three week course of immunization followed by an eleven week rest period, persistent antibody responses were evident along with enhanced IgA response in serum and in lung Broncho-Alveolar Lavage (BAL).
Lo, D.D. et al. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnology. 15, 71 (2012).
Infectious Agents, Infectious Pathway, Mucosal Vaccination, M cells, Th2, intranasal, vaccine, mucosal, IgA, cold chain, influenza